Skip to main content

Displaying 1 - 20 of 1899

Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)

The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
221 0114
Docket Number
9437
Case Status
Pending

Chevron/Hess, In the Matter of

The Federal Trade Commission took action to resolve antitrust concerns related to Chevron Corporation’s acquisition of rival oil producer Hess Corporation by approving a proposed consent order that would prohibit Chevron from appointing Hess CEO John B. Hess to its Board of Directors.

The FTC’s complaint alleges that Mr. Hess communicated publicly and privately with the past and current Secretaries General of the Organization of Petroleum Exporting Countries (OPEC) and an official from Saudi Arabia. In these communications, Mr. Hess stressed the importance of oil market stability and inventory management and encouraged these officials to take actions on these issues and speak about them at different events, the complaint alleges.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
241 0008
Case Status
Pending

Ryan Cohen, US v.

In September 2024, the FTC announced that Ryan Cohen, managing partner of RC Ventures, LLC, and Chairman and CEO of GameStop Corp., will pay a $985,320 civil penalty to settle charges that his acquisition of Wells Fargo & Company shares violated the Hart-Scott-Rodino Act.

Type of Action
Federal
Last Updated
Case Status
Pending